Olanzapine/samidorphan
Overview
Olanzapine/samidorphan, sold under the brand name Lybalvi, is a fixed-dose combination medication for the treatment of schizophrenia and bipolar I disorder. It contains olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist. Samidorphan reduces the weight gain associated with olanzapine while still allowing olanzapine to exert its therapeutic effect. The formulation was approved for medical use in the United States in May 2021.[1–6] WP
Chemistry
Harm reduction information
No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.
User reports
Erowid erowid.org
ListingsBluelight bluelight.org
ListingsReddit reddit.com
ListingsPop culture
No references added yet.
Add a reference
Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.
Opens when accounts launch.
Sources
- Journal / agency Lybalvi- olanzapine and samidorphan l-malate tablet, film coated. 24 February 2022
- Journal / agency Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C. Improving Current Treatments for Schizophrenia. Drug Development Research. 2016. doi:10.1002/ddr.21337 · PMID 27633376
- Journal / agency Fellner C. New Schizophrenia Treatments Address Unmet Clinical Needs. P T. 2017. PMID 28163559 · PMC5265239
- Journal / agency Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf MS, Silverman B, DiPetrillo L, Cummings H, Sun L, McDonnell D. An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder. Neuropsychiatr Dis Treat. 2021. doi:10.2147/NDT.S313840 · PMID 34526769 · PMC8437420
- Journal / agency Paik J. Olanzapine/Samidorphan: First Approval. Drugs. August 2021. doi:10.1007/s40265-021-01568-0 · PMID 34304374
- Journal / agency Drug Approval Package: Lybalvi. 26 June 2021
Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.